3 ms·
As you can see from the lack of biosimilars in the US, manufacturing a biological is a hell of a lot more complex and expensive than doing it for a small molecu
by refurb 8y ago
As you can see from the lack of biosimilars in the US, manufacturing a biological is a hell of a lot more complex and expensive than doing it for a small molecule.
And in fact, since this is version 1.0, I’ll bet a better version comes out before any generic company launches.
- akvadrako 8y agoIf they come out with a new version, they must be expecting it to sell in a quantity that makes the investment worth it. So maybe the pricing worry is just a temporary concern.